Finder makes money from featured partners, but editorial opinions are our own. Advertiser Disclosure
How to buy Medicenna Therapeutics Corp stock
Learn how to easily invest in Medicenna Therapeutics Corp stock.
Medicenna Therapeutics Corp is a biotechnology business based in the US. Medicenna Therapeutics Corp shares (MDNA) are listed on the NASDAQ and all prices are listed in US Dollars. Medicenna Therapeutics Corp employs 13 staff and has a market cap (total outstanding shares value) of 0.00.
How to buy shares in Medicenna Therapeutics Corp
- Compare share trading platforms. Use our comparison table to help you find a platform that fits you.
- Open your brokerage account. Complete an application with your details.
- Confirm your payment details. Fund your account.
- Research the stock. Find the stock by name or ticker symbol – MDNA – and research it before deciding if it's a good investment for you.
- Purchase now or later. Buy your desired number of shares with a market order or use a limit order to delay your purchase until the stock reaches a desired price.
- Check in on your investment. Optimize your portfolio by tracking your stock.
Medicenna Therapeutics Corp stock price (NASDAQ: MDNA)Use our graph to track the performance of MDNA stocks over time.
Medicenna Therapeutics Corp shares at a glance
|Latest market close||$1.19|
|52-week range||$0.76 - $3.69|
|50-day moving average||$1.03|
|200-day moving average||$1.66|
|Wall St. target price||$7.98|
|Dividend yield||$0 (0%)|
|Earnings per share (TTM)||$-0.36|
Buy Medicenna Therapeutics Corp shares from these brokeragesCompare special offers, low fees and a wide range of types of investments among top trading platforms.
*Signup bonus information updated weekly.
The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.
Is it a good time to buy Medicenna Therapeutics Corp stock?
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
Medicenna Therapeutics Corp price performance over time
|1 week (2022-06-23)||11.21%|
|1 month (2022-05-27)||17.82%|
|3 months (2022-03-28)||-8.46%|
|6 months (2021-12-30)||-28.31%|
|1 year (2021-06-30)||-60.47%|
|2 years (2020-06-30)||-67.22%|
|3 years (2019-06-28)||5.31%|
|5 years (2017-06-26)||N/A|
Medicenna Therapeutics Corp financials
|Gross profit TTM||$0|
|Return on assets TTM||-50.17%|
|Return on equity TTM||-87.05%|
|Market capitalisation||$60.1 million|
TTM: trailing 12 months
Medicenna Therapeutics Corp share dividends
We're not expecting Medicenna Therapeutics Corp to pay a dividend over the next 12 months.
Medicenna Therapeutics Corp share price volatility
Over the last 12 months, Medicenna Therapeutics Corp's shares have ranged in value from as little as $0.76 up to $3.69. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Medicenna Therapeutics Corp's is 0.4301. This would suggest that Medicenna Therapeutics Corp's shares are less volatile than average (for this exchange).
Medicenna Therapeutics Corp overview
Medicenna Therapeutics Corp. , a clinical stage immunotherapy company, engages in the development and commercialization of Superkines and empowered Superkines for the treatment of cancer and other diseases. Its lead product is MDNA55, an interleukin- 4 (IL-4) EC that has completed Phase 2b clinical trial for the treatment of recurrent glioblastoma (rGBM), as well as preclinical and clinical development stages for the treatment of other brain and non-brain tumors. The company also develops MDNA55, which has completed Phase 2b clinical trial to treat rGBM; MDNA109, an enhanced version of IL-2 to activate and proliferate the immune cells needed to fight cancer; MDNA209, an IL-2 antagonist for autoimmune diseases, such as multiple sclerosis and graft versus host disease (GvHD); MDNA413, a dual IL-4/IL-13 antagonist to treat solid tumors; and MDNA132, an IL-13 Superkine to chimeric antigen receptor T (CAR-T) platform. In addition, it provides BiSKITs platform to develop designer Superkines by fusing them to other proteins, antibodies, or naked IL-2, IL-4, and IL-13 Superkines. Medicenna Therapeutics Corp. is headquartered in Toronto, Canada.
Medicenna Therapeutics Corp in the news
MDNA: Encouraging CD8+ T Cell and NK Cell Responses in ABILITY Trial…
Market Sentiment Around Loss-Making Medicenna Therapeutics Corp. (TSE:MDNA)
Medicenna Reports Fiscal Year 2022 Financial Results and Operational Highlights
Frequently asked questionsWhat percentage of Medicenna Therapeutics Corp is owned by insiders or institutions?
Currently 32.957% of Medicenna Therapeutics Corp shares are held by insiders and 6.825% by institutions. How many people work for Medicenna Therapeutics Corp?
Latest data suggests 13 work at Medicenna Therapeutics Corp. When does the fiscal year end for Medicenna Therapeutics Corp?
Medicenna Therapeutics Corp's fiscal year ends in March. Where is Medicenna Therapeutics Corp based?
Medicenna Therapeutics Corp's address is: 2 Bloor Street West, Toronto, ON, Canada, M4W 3E2 What is Medicenna Therapeutics Corp's ISIN number?
Medicenna Therapeutics Corp's international securities identification number is: CA58490H1073
More guides on Finder
How to buy Intchains Group (ICG) stock when it goes public
Everything we know about the Intchains Group IPO, plus information on how to buy in.
How to buy Biostage (BSTG) stock when it goes public
Everything we know about the Biostage IPO, plus information on how to buy in.
How to buy Wang & Lee Group (WLGS) stock when it goes public
Everything we know about the Wang & Lee Group IPO, plus information on how to buy in.
How to buy OptMed (OMED) stock when it goes public
Everything we know about the OptMed IPO, plus information on how to buy in.
How to buy Lichen China (LICN) stock when it goes public
Everything we know about the Lichen China IPO, plus information on how to buy in.
How to buy LeeWay Services stock when it goes public
Everything we know about the LeeWay Services IPO, plus information on how to buy in.
How to buy Nano Labs (NA) stock when it goes public
Everything we know about the Nano Labs IPO, plus information on how to buy in.
How to buy Warrantee (WRNT) stock when it goes public
Everything we know about the Warrantee IPO, plus information on how to buy in.
How to buy Treasure Global (TGL) stock when it goes public
Everything we know about the Treasure Global IPO, plus information on how to buy in.
How to buy BIOLIFE4D (SAVU) stock when it goes public
Everything we know about the BIOLIFE4D IPO, plus information on how to buy in.
Ask an Expert